Primary central nervous system lymphoma
G Citterio, M Reni, G Gatta, AJM Ferreri - Critical reviews in oncology …, 2017 - Elsevier
Primary CNS lymphomas (PCNSL) represent a subgroup of malignancies with specific
characteristics, aggressive course, and unsatisfactory outcome in contrast with other …
characteristics, aggressive course, and unsatisfactory outcome in contrast with other …
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients …
AJM Ferreri, K Cwynarski, E Pulczynski… - The Lancet …, 2017 - thelancet.com
Summary Background The International Extranodal Lymphoma Study Group-32 (IELSG32)
trial is an international randomised phase 2 study that addresses two key clinical questions …
trial is an international randomised phase 2 study that addresses two key clinical questions …
Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents
AJM Ferreri - Hematology 2014, the American Society of …, 2017 - ashpublications.org
Primary central nervous system (CNS) lymphomas represent a subgroup of malignancies
with specific characteristics, an aggressive course, and unsatisfactory outcome in contrast …
with specific characteristics, an aggressive course, and unsatisfactory outcome in contrast …
Challenges and opportunities in primary CNS lymphoma: A systematic review
Background: Historically, high-dose methotrexate (HD-MTX) plus consolidation
chemotherapy and/or whole brain radiotherapy (WBRT) has been the gold standard on …
chemotherapy and/or whole brain radiotherapy (WBRT) has been the gold standard on …
Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology
Background Age and performance status are important prognostic factors in primary central
nervous system (CNS) lymphoma. Although several prognostic models have been …
nervous system (CNS) lymphoma. Although several prognostic models have been …
Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS
Aim: To describe the long-term outcomes of patients with lymphoma in the CNS treated with
rituximab, temozolomide and high-dose methotrexate without consolidation therapy …
rituximab, temozolomide and high-dose methotrexate without consolidation therapy …
Cerebrospinal fluid dissemination and neoplastic meningitis in primary brain tumors
S Chowdhary, S Damlo, MC Chamberlain - Cancer Control, 2017 - journals.sagepub.com
Background Neoplastic meningitis, also known as leptomeningeal disease, affects the entire
neuraxis. The clinical manifestations of the disease may affect the cranial nerves, cerebral …
neuraxis. The clinical manifestations of the disease may affect the cranial nerves, cerebral …
Hyperglycemia is associated with poor survival in primary central nervous system lymphoma patients
A Debata, K Yoshida, K Ujifuku, H Yasui… - Tumori …, 2017 - journals.sagepub.com
Purpose Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin
lymphoma (NHL), and it has been postulated that metabolic disorder may contribute to NHL …
lymphoma (NHL), and it has been postulated that metabolic disorder may contribute to NHL …
Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central …
Y Miyakita, M Ohno, M Takahashi… - Japanese Journal of …, 2017 - academic.oup.com
Background There is increasing evidence that MTX-based chemotherapy is superior to HD-
MTX alone. Rituximab (RTX) is effective in a variety of B-cell lymphomas and may enter the …
MTX alone. Rituximab (RTX) is effective in a variety of B-cell lymphomas and may enter the …
Impact of treatment variability on survival in immuno‐competent and immuno‐compromised patients with primary central nervous lymphoma
R Karmali, C Nabhan, AM Petrich… - British Journal of …, 2017 - Wiley Online Library
Patients with primary central nervous system lymphoma (PCNSL) treated in the 'real‐
world'setting do not represent those treated on clinical trials and might not be treated …
world'setting do not represent those treated on clinical trials and might not be treated …